CLINICAL TRIALS PROFILE FOR TETRAHYDROCANNABIVARIN
✉ Email this page to a colleague
Clinical Trials for Tetrahydrocannabivarin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01217112 ↗ | GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes | Completed | GW Research Ltd | Phase 2 | This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes. This is the first study to determine whether the study medications have a positive benefit for subjects on their cholesterol levels, body weight, liver fat content and other metabolic parameters compared with a placebo medication. |
| NCT02053272 ↗ | A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes | Completed | GW Research Ltd | Phase 2 | A study to compare the change in glycaemic control in participants with Type 2 diabetes when treated with GWP42004 or placebo as add-on therapy to metformin over a period of 12 weeks. The safety and tolerability of GWP42004 compared with placebo will also be assessed. |
| NCT04842383 ↗ | Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series | Recruiting | Gregory L Smith, MD, MPH | Early Phase 1 | This is a case series of adult, male and female subjects with androgenetic alopecia (male pattern baldness). A topical hemp oil that is rich in varins (THCV and CBDV) and cannabidiol (CBD) is being used daily for six months to stimulate hair regrowth using Endocannabinoid System (ECS) receptors that are found on hair follicles. |
| NCT05574049 ↗ | Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips | Completed | Medical Life Care Planners, LLC | Early Phase 1 | The goal of this clinical trial is to compare the efficacy of two different daily doses of tetrahydrocannabivarin impregnated mouth strips in healthy non-diabetic obese adults. The main questions to answer are: - Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels? - Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels? - Is one dose better than the other dose? Participants will take either the low dose, high dose or placebo dose daily for ninety days and have physical measurements and blood tests obtained at the beginning and the end of the study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tetrahydrocannabivarin
Condition Name
Clinical Trial Locations for Tetrahydrocannabivarin
Trials by Country
Clinical Trial Progress for Tetrahydrocannabivarin
Clinical Trial Phase
Clinical Trial Sponsors for Tetrahydrocannabivarin
Sponsor Name
